Identification of novel variants of the flavin-containing monooxygenase gene family in African Americans

Drug Metabolism and Disposition

Volumn 31, Issue 2, 2003, Pages 187-193

  Furnes, Bjarte ^a   Feng, Jinong ^b   Sommer, Steve S ^b   Schlenk, Daniel ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; DIMETHYLANILINE MONOOXYGENASE; PESTICIDE; XENOBIOTIC AGENT;

ALLELE; ARTICLE; CATALYSIS; ECOTOXICOLOGY; ENZYME POLYMORPHISM; FMO1 GENE; FMO2 GENE; FMO3 GENE; FMO4 GENE; FMO5 GENE; FMO6 GENE; GENE; GENE IDENTIFICATION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; MISSENSE MUTATION; NEGRO; NONHUMAN; NONSENSE MUTATION; NUCLEOTIDE SEQUENCE; OXYGENATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STRUCTURE; SINGLE STRAND CONFORMATION POLYMORPHISM; SPLICEOSOME; XENOBIOTIC METABOLISM;

AFRICAN AMERICANS; AFRICAN CONTINENTAL ANCESTRY GROUP; GENE FREQUENCY; HUMANS; OXYGENASES; POLYMORPHISM, SINGLE NUCLEOTIDE; VARIATION (GENETICS);

EID: 12244306252     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.31.2.187     Document Type: Article

References (39)

1. Agundez JA, Gallardo L, Ledesma MC, Lozano L, Rodriguez-Lescure A, Pontes JC, Iglesias-Moreno MC, Poch J, Ladero JM, and Benitez J (2001) Functionally active duplications of the CYP2D6 gene are more prevalent among larynx and lung cancer patients. Oncology 61:59-63.
2. Bertilsson L, Dahl ML, Dalen P, and Al-Shurbaji A (2002) Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol 53:111-122.
3. Board P, Blackburn A, Jermiin LS, and Chelvanayagam G (1998) Polymorphism of phase II enzymes: identification of new enzymes and polymorphic variants by database analysis. Toxicol Lett 102-103:149-154.
4. Burchell B and Hume R (1999) Molecular genetic basis of Gilbert's syndrome. J Gastroenterol Hepatol 14:960-966.
5. Buzin CH, Wen CY, Nguyen VQ, Nozari G, Mengos A, Li X, Chen JS, Liu Q, Gatti RA, Fujimura FK, and Sommer SS (2000) Scanning by DOVAM-S detects all unique sequence changes in blinded analyses: evidence that the scanning conditions are generic. Biotechniques 28:746-750, 752-743.
6. Cashman JR (1995) Structural and catalytic properties of the mammalian flavin-containing monooxygenase. Chem Res Toxicol 8:165-181.
7. Cashman JR, Bi Y, Lin J, Youil R, Knight M, Forrest S, and Treacy E (1997) Human flavin-containing monooxygenase form 3: cDNA expression of the enzymes containing amino acid substitutions observed in individuals with trimethylaminuria. Chem Res Toxicol 10:837-841.
8. Cashman JR, Park SB, Yang ZC, Washington CB, Gomez DY, Giacomini KM, and Brett CM (1993) Chemical enzymatic and human enantioselective S-oxygenation of cimetidine. Drug Metab Dispos 21:587-597.
9. Cashman JR, Zhang J, Leushner J, and Braun A (2001) Population distribution of human flavin-containing monooxygenase form 3: gene polymorphisms. Drug Metab Dispos 29:1629-1637.
10. Chung WG, Park CS, Roh HK, Lee WK, and Cha YN (2000) Oxidation of ranitidine by isozymes of flavin-containing monooxygenase and cytochrome P450. Jpn J Pharmacol 84:213-220.
11. Dolphin CT, Beckett DJ, Janmohamed A, Cullingford TE, Smith RL, Shephard EA, and Phillips IR (1998) The flavin-containing monooxygenase 2 gene (FMO2) of humans, but not of other primates, encodes a truncated, nonfunctional protein. J Biol Chem 273:30599-30607.
12. Dolphin CT, Cullingford TE, Shepard EA, Smith RL, and Phillips IR (1996) Differential developmental and tissue-specific regulation of expression of the genes encoding three members of the flavin-containing monooxygenase family in man, FMO1, FMO3, and FMO4. Eur J Biochem 235:683-689.
13. Dolphin CT, Janmohamed A, Smith RL, Shephard EA, and Phillips IR (1997) Missense mutation in flavin-containing mono-oxygenase 3 gene, FMO3, underlies fish-odour syndrome. Nat Genet 17:491-494.
14. Elfarra AA (1995) Potential role of the flavin-containing monooxygenases in the metabolism of endogenous compounds. Chem Biol Interact 96:47-55.
15. Falls JG, Ryu DY, Cao Y, Levi PE, and Hodgson E (1997) Regulation of mouse liver flavin-containing monooxygenases 1 and 3 by sex steroids. Arch Biochem Biophys 342:212-223.
16. Gustafson S, Proper JA, Bowie EJ, and Sommer SS (1987) Parameters affecting the yield of DNA from human blood. Anal Biochem 165:294-299.
17. Hajjar NP and Hodgson E (1980) Flavin adenine dinucleotide-dependent monooxygenase: its role in the sulfoxidation of pesticides in mammals. Science (Wash DC) 209:1134-1136.
18. Hassett C, Aicher L, Sidhu JS, and Omiecinski CJ (1994) Human microsomal epoxide hydrolase: genetic polymorphism and functional expression in vitro of amino acid variants. Hum Mol Genet 3:421-428.
19. Hines RN, Hopp KA, Franco J, Saeian K, and Begun FP (2002) Alternative processing of the human FMO6 gene renders transcripts incapable of encoding a functional flavin-containing monooxygenase. Mol Pharmacol 62:320-325.
20. Hodgson E, Rose RL, Cao Y, Dehal SS, and Kupfer D (2000) Flavin-containing monooxygenase isoform specificity for the N-oxidation of tamoxifen determined by product measurement and NADPH oxidation. J Biochem Mol Toxicol 14:118-120.
21. Itagaki K, Carver GT, and Philpot RM (1996) Expression and characterization of a modified flavin-containing monooxygenase 4 from humans. J Biol Chem 271:20102-20107.
22. Koukouritaki SB, Simpson P, Yeung CK, Rettie AE, and Hines RN (2002) Human hepatic flavin-containing monooxygenases 1 (FMO1) and 3 (FMO3) developmental expression. Pediatr Res 51:236-243.
23. Lawton MP and Philpot RM (1993) Functional characterization of flavin-containing monooxygenase 1B1 expressed in Saccharomyces cerevisiae and Escherichia coli and analysis of proposed FAD- and membrane-binding domains. J Biol Chem 268:5728-5734.
24. Liu Q, Feng J, Buzin C, Wen C, Nozari G, Mengos A, Nguyen V, Liu J, Crawford L, Fujimura FK, and Sommer SS (1999) Detection of virtually all mutations-SSCP (DOVAM-S): a rapid method for mutation scanning with virtually 100% sensitivity. Biotechniques 26:932, 936-938, 940-942.
25. Lomri N, Gu Q, and Cashman JR (1992) Molecular cloning of the flavin-containing monooxygenase (form II) cDNA from adult human liver. Proc Natl Acad Sci USA 89:1685-1689.
26. McCombie RR, Dolphin CT, Povey S, Phillips IR, and Shephard EA (1996) Localization of human flavin-containing monooxygenase genes FMO2 and FMO5 to chromosome 1q. Genomics 34:426-429.
27. Mihaly GW and Morgan DJ (1983) Placental drug transfer: effects of gestational age and species. Pharmacol Ther 23:253-266.
28. Miller MM, James RA, Richer JK, Gordon DF, Wood WM, and Horwitz KB (1997) Progesterone regulated expression of flavin-containing monooxygenase 5 by the B-isoform of progesterone receptors: implications for tamoxifen carcinogenicity. J Clin Endocrinol Metab 82:2956-2961.
29. Overby LH, Buckpitt AR, Lawton MP, Atta-Asafo-Adjei E, Schulze J, and Philpot RM (1995) Characterization of flavin-containing monooxygenase 5 (FMO5) cloned from human and guinea pig: evidence that the unique catalytic properties of FMO5 are not confined to the rabbit ortholog. Arch Biochem Biophys 317:275-284.
30. Overby LH, Carver GC, and Philpot RM (1997) Quantitation and kinetic properties of hepatic microsomal and recombinant flavin-containing monooxygenases 3 and 5 from humans. Chem Biol Interact 106:29-45.
31. Phillips IR, Dolphin CT, Clair P, Hadley MR, Hutt AJ, McCombie RR, Smith RL, and Shephard EA (1995) The molecular biology of the flavin-containing monooxygenases of man. Chem Biol Interact 96:17-32.
32. Shephard EA, Dolphin CT, Fox MF, Povey S, Smith R, and Phillips IR (1993) Localization of genes encoding three distinct flavin-containing monooxygenases to human chromosome 1q. Genomics 16:85-89.
33. Tang C, Shou M, Rushmore TH, Mei Q, Sandhu P, Woolf EJ, Rose MJ, Gelmann A, Greenberg HE, De Lepeleire I, et al. (2001) In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9: correlation with CYP2C9 genotype and in-vivo pharmacokinetics. Pharmacogenetics 11:223-235.
34. Treacy EP, Akerman BR, Chow LM, Youil R, Bibeau C, Lin J, Bruce AG, Knight M, Danks DM, Cashman JR, and Forrest SM (1998) Mutations of the flavin-containing monooxygenase gene (FMO3) cause trimethylaminuria, a defect in detoxication. Hum Mol Genet 7:839-845.
35. Weber WW (1999) Populations and genetic polymorphisms. Mol Diagn 4:299-307.
36. Whetstine JR, Yueh MF, McCarver DG, Williams DE, Park CS, Kang JH, Cha YN, Dolphin CT, Shephard EA, Phillips IR, and Hines RN (2000) Ethnic differences in human flavin-containing monooxygenase 2 (FMO2) polymorphisms: detection of expressed protein in African-Americans. Toxicol Appl Pharmacol 168:216-224.
37. Wrighton SA and Vandenbranden M (1989) Isolation and characterization of human fetal liver cytochrome P450HLp2: a third member of the P450III gene family. Arch Biochem Biophys 268:144-151.
38. Yeung CK, Lang DH, Thummel KE, and Rettie AE (2000) Immunoquantitation of FMO1 in human liver, kidney and intestine. Drug Metab Dispos 28:1107-1111.
39. Ziegler-Skylakakis K, Nill S, Pan JF, and Andrae U (1998) S-oxygenation of thiourea results in the formation of genotoxic products. Environ Mol Mutagen 31:362-373.